Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 3Carcinoma, Renal Cell 2Uveal Melanoma 1Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Kidney Neoplasms 1

Interventions

Cytarabine 61Daunorubicin 28Specimen Handling 24Etoposide 24Azacitidine 22Decitabine 19Cyclophosphamide 19fludarabine phosphate 18Filgrastim 18Biopsy 18Busulfan 17Idarubicin 16venetoclax 15Peripheral Blood Stem Cell Transplantation 15Mitoxantrone 15Injections 14Vorinostat 12tipifarnib 11Bortezomib 10decitabine and cedazuridine drug combination 9Radiotherapy 9Methotrexate 9alvocidib 8Cyclosporine 8sargramostim 7Melphalan 7Antilymphocyte Serum 7laromustine 6fludarabine 6aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Acute × flt3 ligand protein × Clear all
NCT00006223 2013-06-24

flt3L in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡